Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corporation on October 2, 2015, reporting an event dated October 1, 2015. The filing details an addendum to a Supply Agreement between ChromaDex, Inc. (a wholly owned subsidiary) and Nectar7 LLC ("Nectar"). The agreement concerns the exclusive distribution rights for NIAGEN® dietary supplements combined with collagen in the United States.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. It focuses exclusively on the terms of a material definitive agreement.
- Take or Pay Guarantee (2016): $2 million
- Take or Pay Guarantee (2017): $3 million
- Take or Pay Guarantee (2018): $3 million
- Future Guarantees: Negotiated in good faith, with a floor of $3 million per year.
Material Changes and Agreement Terms
The primary material change is the expansion of exclusive rights granted to Nectar7 LLC. Under the Addendum, Nectar received exclusive rights to sell dietary supplements containing a combination of NIAGEN® and collagen in tablet, capsule, powder, liquid, or spray form in the United States for a five-year term.
Key contractual conditions include:
- Exclusivity Retention: Nectar must meet the specified take or pay guarantees to retain exclusivity.
- Termination by Nectar: Nectar may cancel the take or pay obligation for 2017 and beyond with 90 days' written notice, which simultaneously terminates exclusivity.
- Termination by ChromaDex: ChromaDex may terminate exclusivity for specific product applications if Nectar fails to meet "Minimum Revenues" for indicated time periods.
- Renewal: The agreement automatically renews for successive five-year terms per product application if Minimum Revenues are met.
Guidance, Outlook, and Risks
The filing does not provide general financial guidance or outlook. However, it outlines specific risks and contingencies related to the Nectar Agreements:
- Revenue Risk: ChromaDex's ability to retain exclusivity depends on Nectar meeting minimum revenue thresholds.
- Contractual Uncertainty: Future take or pay guarantees beyond 2018 are subject to negotiation, though they cannot fall below $3 million.
- Confidentiality: Certain terms of the Nectar Agreements are subject to confidential treatment and will be filed as exhibits to the Form 10-Q for the quarter ended October 3, 2015.
Investor Verification Checklist
- Verify the full text of the Nectar Agreements in the upcoming Form 10-Q for the quarter ended October 3, 2015, as specific terms are under confidential treatment.
- Confirm the definition of "Minimum Revenues" required to prevent termination of exclusivity by ChromaDex.
- Monitor Nectar7 LLC's market performance to assess the likelihood of meeting the $2 million (2016) and $3 million (2017-2018) take or pay guarantees.
- Clarify the distinction between the parent company (ChromaDex Corporation) and the subsidiary (ChromaDex, Inc.) regarding the execution of the agreement.